Revvity had its Relative Strength (RS) Rating upgraded from 67 to 73 Wednesday — a welcome improvement, but still below the 80 or higher score you look for.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best stocks often have an RS Rating of over 80 in the early stages of their moves. See if Revvity can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Revvity is trying to complete a consolidation with a 129.50 entry. See if the stock can clear the breakout price in volume at least 40% above average.
In terms of fundamentals, the company has posted three quarters of accelerating earnings growth. Sales growth has also risen over the same time frame. The company is expected to report its next quarterly numbers on or around Jan. 29.
The company holds the No. 15 rank among its peers in the Medical-Research Equipment/Services industry group. Champions Oncology, Veracyte and Natera are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
